InvestorsHub Logo
Followers 74
Posts 11211
Boards Moderated 1
Alias Born 02/13/2014

Re: DewDiligence post# 833

Thursday, 06/22/2017 8:20:36 PM

Thursday, June 22, 2017 8:20:36 PM

Post# of 6070
I think PFE funded something for XXII in the past. And then there's this from April:

22nd Century Accepted to Present Proprietary Smoking Cessation Product at BIOCHINA Partnering Forum in Zhuhai, China
By Business Wire, April 25, 2017, 09:45:00 AM EDT

"......Recent rule changes by the Chinese Food and Drug Administration (CFDA) will open an expedited pathway for X-22 in China. Under the old rules, China lagged behind other countries in approving important medicines. In announcing the proposed new rules, China's CFDA Director, Bi Jingquan, promised to speed up foreign drug approvals in China and, in support of such desired result, the CFDA has already quadrupled the CFDA's staff of Drug Team Reviewers. Major pharmaceutical giants, including Pfizer (NYSE:PFE), AstraZeneca (NYSE:AZN), and Novo Nordisk (NYSE:NVO), have already expressed their approval of the new CFDA rules in China, which include: (i) expedited regulatory processes for new drugs, which shorten approval processes in China from over 2-years to just 12 months, (ii) an expansion of China's "green channel" fast-track pathway for important new drugs, and (iii) waiving the requirement for a China-specific trial when a multi-regional clinical trial is conducted."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News